Compare · ALC vs RXST
ALC vs RXST
Side-by-side comparison of Alcon Inc. (ALC) and RxSight Inc. (RXST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALC and RXST operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- ALC is the larger of the two at $33.13B, about 150.1x RXST ($220.6M).
- Over the past year, ALC is down 22.2% and RXST is down 65.7% - ALC leads by 43.6 points.
- RXST has been more active in the news (2 items in the past 4 weeks vs 1 for ALC).
- Both have 25 recent analyst ratings on file.
- Company
- Alcon Inc.
- RxSight Inc.
- Price
- $66.28+0.92%
- $5.32-4.40%
- Market cap
- $33.13B
- $220.6M
- 1M return
- -9.00%
- -22.17%
- 1Y return
- -22.16%
- -65.74%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2021
- News (4w)
- 1
- 2
- Recent ratings
- 25
- 25
Alcon Inc.
Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; and EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, including devices and over-the-counter products for dry eye, over-the-counter products for contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon, Inc. in December 2001. Alcon, Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
RxSight Inc.
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
Latest ALC
- SEC Form SD filed by Alcon Inc.
- SEC Form 6-K filed by Alcon Inc.
- New Product Launches Drive Alcon's First-Quarter 2026 Growth as Momentum from Unity and Tryptyr Builds
- Alcon Announces Results of 2026 Annual General Meeting
- Systane Steps Up to the Plate as the Official Eye Drop of the Toronto Blue Jays, Raising Awareness of Dry Eye in Canada
- Alcon Launches Clareon TruPlus, Enhanced Design Monofocal and Toric IOLs, at ASCRS 2026
- SEC Form 6-K filed by Alcon Inc.
- Alcon Publishes Agenda for 2026 Annual General Meeting
- Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement
- Alcon Surpasses 175 Million IOLs Implanted Globally
Latest RXST
- SEC Form SD filed by RxSight Inc.
- RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
- SEC Form 10-Q filed by RxSight Inc.
- RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook
- RxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- RxSight, Inc. to Present at the Bank of America Healthcare Conference
- SEC Form DEFA14A filed by RxSight Inc.
- SEC Form DEF 14A filed by RxSight Inc.
- RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
- SEC Form 4 filed by Goldshleger Ilya